Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen

Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Edward GaneGS-US-342-1553 Investigators

Abstract

The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct-acting antiviral-based therapies remains unclear. In this multicenter, open-label, phase 2 study, we evaluated the efficacy and safety of a fixed-dose combination of sofosbuvir-velpatasvir (400 mg/100 mg) plus weight-adjusted ribavirin administered for 24 weeks in patients who did not achieve sustained virologic response after prior treatment with direct-acting antiviral regimens that included the nucleotide analogue nonstructural protein 5B inhibitor sofosbuvir plus the nonstructural protein 5A inhibitor velpatasvir with or without the nonstructural protein 3/4A protease inhibitor voxilaprevir. The primary efficacy endpoint was the proportion of patients achieving sustained virologic response at 12 weeks after the cessation of treatment. In total, 63 of 69 (91%; 95% confidence interval, 82%-97%) patients achieved sustained virologic response at 12 weeks, including 36 of 37 (97%; 95% confidence interval, 86%-100%) patients with hepatitis C virus genotype 1 infection, 13 of 14 (93%; 95% confidence interval, 66%-100%) patients with genotype 2 infection, and 14 of 18 (78%; 95% confi...Continue Reading

References

Sep 4, 2015·Therapeutic Advances in Gastroenterology·Brian P LamZobair M Younossi
Nov 17, 2015·The New England Journal of Medicine·Michael P CurryUNKNOWN ASTRAL-4 Investigators
Nov 17, 2015·The New England Journal of Medicine·Jordan J FeldUNKNOWN ASTRAL-1 Investigators
Nov 18, 2015·The New England Journal of Medicine·Graham R FosterUNKNOWN ASTRAL-3 Investigators
Nov 21, 2015·Hepatic Medicine : Evidence and Research·Jacinta A Holmes, Alexander J Thompson
Jul 31, 2016·Liver International : Official Journal of the International Association for the Study of the Liver·Jordan J FeldJean-Michel Pawlotsky

❮ Previous
Next ❯

Citations

Feb 11, 2018·Liver International : Official Journal of the International Association for the Study of the Liver·Vincenza CalvarusoAntonio Craxì
Jun 20, 2018·The Journal of General Virology·Yuji TeraokaKazuaki Chayama
Aug 6, 2017·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Simone I Strasser
Aug 11, 2018·Clinical and Molecular Hepatology·UNKNOWN Korean Association for the Study of the Liver (KASL)
Feb 26, 2019·Clinical and Molecular Hepatology·Shinya SatoHitoshi Yoshiji
May 23, 2019·Clinical Pharmacokinetics·Elise J SmoldersDavid M Burger
Jul 30, 2019·Liver International : Official Journal of the International Association for the Study of the Liver·Timothy PapalucaAlexander Thompson
May 3, 2019·Clinical and Molecular Hepatology·Tommaso Lorenzo ParigiAlessio Aghemo
Mar 20, 2020·Clinical and Molecular Hepatology·Chung-Feng Huang, Ming-Lung Yu
Oct 12, 2018·Viruses·Pierre PradatEric Trépo
Feb 23, 2019·Expert Review of Gastroenterology & Hepatology·Lucia Parlati, Stanislas Pol
Jul 10, 2019·Journal of Gastroenterology and Hepatology·Simone I StrasserUNKNOWN Clinical Cases in Hepatitis 2018 Steering Committee
Apr 17, 2020·Open Forum Infectious Diseases·Daniel S Fierer, David L Wyles
Sep 6, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mark Sulkowski, David Wyles
Nov 28, 2020·The Journal of Infectious Diseases·Oluwaseun Falade-Nwulia, Mark S Sulkowski
Nov 22, 2020·Journal of Hepatology·Julia DietzUNKNOWN Members of the German HCV resistance study group
Jan 26, 2021·JGH Open : an Open Access Journal of Gastroenterology and Hepatology·Satoshi TakakusagiToshio Uraoka
May 2, 2020·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Ming-Lung YuWan-Long Chuang
Sep 6, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Timothy PapalucaAlexander J Thompson
May 21, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Caroline E BoekeChristian B Ramers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.